Article
MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
Cancer research - 15 Aug 1997
Brünner N, Boysen B, Jirus S, Skaar T C, Holst-Hansen C, Lippman J, Frandsen T, Spang-Thomsen M, Fuqua S A, Clarke R
Abstract excerpt
Acquired resistance to antiestrogens is a major problem in the clinical management of initially endocrine responsive metastatic breast cancer. We have shown previously that estrogen-independent and -responsive MCF7/LCC1 human breast cancer cells selected for resistance to the triphenylethylene tamoxifen produce a variant (MCF7/LCC2) that retains sensitivity to the steroidal antiestrogen ICI 182,780 (N. Brunner et...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.